This episode of "This Week in Virology" provides a clinical update on several viral diseases and public health topics. The hosts conduct a detailed retrospective on the 2020 Great Barrington Declaration, contrasting its core assumptions—negligible risk in youth and lasting natural immunity—with the more cautious, evidence-based John Snow Memorandum. This historical context is linked to current public health controversies, including a lawsuit filed by major medical groups against HHS and its secretary, RFK Jr., for "arbitrarily and capriciously" changing COVID-19 vaccine policies.
The update covers alarming new data on pediatric infectious diseases, including a record-breaking measles outbreak in the U.S., a severe influenza season with over 250 pediatric deaths, and significant COVID-19 hospitalizations among children. The episode also highlights new research, presenting studies on the association between adjuvanted vaccines (for shingles and RSV) and a reduced risk of dementia, the high rate of hospital readmission for children with RSV, and the ineffectiveness of Remdesivir in preventing long COVID. Finally, promising results from a Phase 2b trial for a new long-acting influenza preventative drug are discussed.
A Clinical Update on Viral Threats: From the Great Barrington Declaration to Modern-Day Outbreaks
0:05:50 The Great Barrington Declaration (GBD) Revisited: The episode revisits the October 2020 GBD, a proposal advocating for achieving herd immunity through natural infection in the young and healthy. Its core assumptions were that COVID-19 posed a negligible risk to the non-elderly, that infection provided strong and long-lasting immunity, and that the vulnerable could be effectively isolated.
0:11:11 The John Snow Memorandum: A Scientific Rebuttal: In contrast to the GBD, the John Snow Memorandum, published in The Lancet, highlighted the scientific consensus at the time. It correctly noted that immunity might not be long-lasting, reinfection was possible, and uncontrolled transmission in younger people still posed significant risks of morbidity, mortality, and overwhelming healthcare systems.
0:14:50 Current COVID-19 Impact on Children: Recent data presented to the CDC's Advisory Committee on Immunization Practices (ACIP) revealed that in the last 12 months, over 7,000 children were hospitalized with COVID-19, and 152 died. Critically, half of these children were previously healthy, and virtually none had been vaccinated.
0:18:17 Medical Community Sues HHS: Six major medical groups, including the AAP and ISDA, have filed a lawsuit against HHS and Secretary RFK Jr. The suit alleges that recent changes to vaccine policy were made "arbitrarily and capriciously" and are part of an effort to "mislead, confuse, and gradually desensitize the public to anti-vaccine and anti-science rhetoric."
0:21:49 Vaccines and Dementia Risk: A new study suggests that AS01-adjuvanted vaccines (Shingrix for shingles and Arexvy for RSV) are associated with a significantly reduced risk of dementia. The findings suggest the adjuvant itself may play a protective role.
0:28:44 Alarming Measles Outbreak: The U.S. has now recorded 1,288 measles cases in 2025, the highest number in any year since the disease's elimination was declared in 2000.
0:30:38 Severe Influenza Season: The 2024-2025 flu season resulted in 256 pediatric deaths, the highest in any non-pandemic season. Over 90% of the children who died were unvaccinated.
0:32:05 A New Preventative Flu Drug: Sedara Therapeutics announced positive Phase 2b trial results for CD388, a long-acting drug for preventing seasonal influenza (not a vaccine). A single shot demonstrated up to 76.1% efficacy over the 24-week flu season.
0:36:44 The Lingering Impact of RSV: A study found that children under five hospitalized with RSV have a significantly higher risk of respiratory-related readmission. They are 3.6 times more likely to be readmitted within 1.5 years compared to children hospitalized for influenza or human metapneumovirus.
0:45:01 Long COVID Treatment Update: A study on hospitalized COVID-19 patients found that treatment with the antiviral drug Remdesivir did not significantly reduce the risk of developing long-term sequelae (PASC). This is in contrast to vaccination, which remains highly effective at reducing the risk of long COVID.